The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) is a huge mover today! About 676,713 shares traded hands. Sangamo Biosciences, Inc. (NASDAQ:SGMO) has declined 48.07% since April 6, 2016 and is downtrending. It has underperformed by 50.03% the S&P500.
The move comes after 6 months negative chart setup for the $250.93 million company. It was reported on Nov, 8 by Barchart.com. We have $3.02 PT which if reached, will make NASDAQ:SGMO worth $25.09 million less.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) Ratings Coverage
Out of 9 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 4 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 44% are positive. Sangamo Biosciences has been the topic of 12 analyst reports since August 8, 2015 according to StockzIntelligence Inc. Jefferies reinitiated Sangamo Biosciences, Inc. (NASDAQ:SGMO) on Friday, October 23 with “Buy” rating. On Saturday, August 8 the stock rating was maintained by JP Morgan with “Overweight”. The firm has “Buy” rating by JP Morgan given on Thursday, September 3. Wedbush downgraded the shares of SGMO in a report on Tuesday, November 1 to “Neutral” rating. The firm has “Buy” rating given on Wednesday, September 2 by Jefferies. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) has “Neutral” rating given on Wednesday, October 19 by Piper Jaffray. As per Tuesday, September 8, the company rating was downgraded by Zacks. The rating was maintained by Cowen & Co on Friday, September 4 with “Buy”. The rating was maintained by Wedbush with “Buy” on Wednesday, September 2. Wells Fargo initiated the stock with “Outperform” rating in Friday, December 4 report.
According to Zacks Investment Research, “Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.”
Insitutional Activity: The institutional sentiment decreased to 0.81 in Q2 2016. Its down 0.57, from 1.38 in 2016Q1. The ratio dived, as 20 funds sold all Sangamo Biosciences, Inc. shares owned while 42 reduced positions. 13 funds bought stakes while 37 increased positions. They now own 45.72 million shares or 4.72% less from 47.99 million shares in 2016Q1.
Moreover, Barclays Public Limited Com has 0% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 16,299 shares. Price T Rowe Associates Md owns 98,500 shares or 0% of their US portfolio. Raymond James Incorporated has invested 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Wasatch Advsr has invested 0.62% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Weiss Multi, a Alabama-based fund reported 32,805 shares. Bourgeon Capital Ltd Company last reported 49,000 shares in the company. Moreover, Tiaa Cref Inv Management Ltd Com has 0% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 316,851 shares. Schwab Charles Invest Management accumulated 0% or 264,847 shares. Capital Fin Advisers Ltd Liability Company owns 32,214 shares or 0% of their US portfolio. Jpmorgan Chase & holds 0% or 771 shares in its portfolio. Sit Associate last reported 26,725 shares in the company. Brick & Kyle Assoc accumulated 0% or 1,100 shares. California State Teachers Retirement, a California-based fund reported 145,781 shares. Blair William And Il accumulated 0% or 10,400 shares. Fic Capital last reported 2.36% of its portfolio in the stock.
More notable recent Sangamo Biosciences, Inc. (NASDAQ:SGMO) news were published by: Fool.com which released: “Why Sangamo Biosciences, Inc. Fell 29% Today” on August 04, 2016, also Prnewswire.com with their article: “Sangamo BioSciences Announces Third Quarter 2016 Conference Call and Webcast” published on October 19, 2016, Prnewswire.com published: “Sangamo BioSciences Announces Participation In Upcoming Scientific Conferences” on October 17, 2016. More interesting news about Sangamo Biosciences, Inc. (NASDAQ:SGMO) were released by: Prnewswire.com and their article: “Sangamo BioSciences Announces Participation At Upcoming Investor Conferences” published on September 29, 2016 as well as Prnewswire.com‘s news article titled: “Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And …” with publication date: June 01, 2016.
SGMO Company Profile
Sangamo Biosciences Inc., incorporated on June 22, 1995, is a clinical-stage biopharmaceutical company. The Firm is focused on the research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. The Firm is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics, which are therapeutic products for the treatment of genetic disease. The Company’s ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is being evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. The Firm has preclinical programs in hemophilia A and other Lysergic acid diethylamide (LSDs), and research stage programs in other monogenic diseases, including certain central nervous system (CNS) disorders and cancer immunotherapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.